 | • レポートコード：MRC23Q36773 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の脳転移治療薬市場について調査・分析し、世界の脳転移治療薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（抗けいれん薬、コルチコステロイド、化学療法薬、その他）、用途別セグメント分析（がん病院、がん研究センター、診療所）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Bayer AG、Pfizer Inc.、Eli Lilly & Company、Novartis AG、Sanofi、F. Hoffmann-La Roche Ltd.、AstraZeneca、GlaxoSmithKline、Merck & Co., Inc.、AngioChem Inc、Mayo Clinicなどが含まれています。世界の脳転移治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、脳転移治療薬市場規模を推定する際に考慮しました。本レポートは、脳転移治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、脳転移治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・脳転移治療薬市場の概要 - 製品の定義 - 脳転移治療薬のタイプ別セグメント - 世界の脳転移治療薬市場規模：タイプ別分析（抗けいれん薬、コルチコステロイド、化学療法薬、その他） - 脳転移治療薬の用途別セグメント - 世界の脳転移治療薬市場規模：用途別分析（がん病院、がん研究センター、診療所） - 世界の脳転移治療薬市場規模予測（2018年-2029年） - 脳転移治療薬の平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - 脳転移治療薬市場の競争状況およびトレンド ・脳転移治療薬の地域別市場規模 - 北米の脳転移治療薬市場規模（2018年-2029年） - アメリカの脳転移治療薬市場規模（2018年-2029年） - ヨーロッパの脳転移治療薬市場規模（2018年-2029年） - アジア太平洋の脳転移治療薬市場規模（2018年-2029年） - 中国の脳転移治療薬市場規模（2018年-2029年） - 日本の脳転移治療薬市場規模（2018年-2029年） - 韓国の脳転移治療薬市場規模（2018年-2029年） - インドの脳転移治療薬市場規模（2018年-2029年） - オーストラリアの脳転移治療薬市場規模（2018年-2029年） - 中南米の脳転移治療薬市場規模（2018年-2029年） - 中東・アフリカの脳転移治療薬市場規模（2018年-2029年） ・タイプ別セグメント：抗けいれん薬、コルチコステロイド、化学療法薬、その他 - 世界の脳転移治療薬のタイプ別販売量（2018年-2023年） - 世界の脳転移治療薬のタイプ別売上（2018年-2023年） - 世界の脳転移治療薬のタイプ別価格 ・用途別セグメント：がん病院、がん研究センター、診療所 - 世界の脳転移治療薬の用途別販売量（2018年-2023年） - 世界の脳転移治療薬の用途別売上（2018年-2023年） - 世界の脳転移治療薬の用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Bayer AG、Pfizer Inc.、Eli Lilly & Company、Novartis AG、Sanofi、F. Hoffmann-La Roche Ltd.、AstraZeneca、GlaxoSmithKline、Merck & Co., Inc.、AngioChem Inc、Mayo Clinic ・産業チェーンと販売チャネルの分析 - 脳転移治療薬産業チェーン分析 - 脳転移治療薬の主要原材料 - 脳転移治療薬の販売チャネル - 脳転移治療薬のディストリビューター - 脳転移治療薬の主要顧客 ・脳転移治療薬市場ダイナミクス - 脳転移治療薬の業界動向 - 脳転移治療薬市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Brain Metastases Treatment Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Brain Metastases Treatment Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Brain Metastases Treatment Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Brain Metastases Treatment Drugs include Bayer AG, Pfizer Inc., Eli Lilly & Company, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., AstraZeneca, GlaxoSmithKline and Merck & Co., Inc., etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Brain Metastases Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Brain Metastases Treatment Drugs.
The Brain Metastases Treatment Drugs market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Brain Metastases Treatment Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Brain Metastases Treatment Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Bayer AG
Pfizer Inc.
Eli Lilly & Company
Novartis AG
Sanofi
F. Hoffmann-La Roche Ltd.
AstraZeneca
GlaxoSmithKline
Merck & Co., Inc.
AngioChem Inc
Mayo Clinic
Segment by Type
Anticonvulsants
Corticosteroids
Chemotherapy Drugs
Others
Segment by Application
Cancer Hospitals
Cancer Research Centers
Clinics
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Brain Metastases Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Brain Metastases Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Brain Metastases Treatment Drugs Market Overview
1.1 Product Overview and Scope of Brain Metastases Treatment Drugs
1.2 Brain Metastases Treatment Drugs Segment by Type
1.2.1 Global Brain Metastases Treatment Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Anticonvulsants
1.2.3 Corticosteroids
1.2.4 Chemotherapy Drugs
1.2.5 Others
1.3 Brain Metastases Treatment Drugs Segment by Application
1.3.1 Global Brain Metastases Treatment Drugs Market Value by Application: (2023-2029)
1.3.2 Cancer Hospitals
1.3.3 Cancer Research Centers
1.3.4 Clinics
1.4 Global Brain Metastases Treatment Drugs Market Size Estimates and Forecasts
1.4.1 Global Brain Metastases Treatment Drugs Revenue 2018-2029
1.4.2 Global Brain Metastases Treatment Drugs Sales 2018-2029
1.4.3 Global Brain Metastases Treatment Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Brain Metastases Treatment Drugs Market Competition by Manufacturers
2.1 Global Brain Metastases Treatment Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Brain Metastases Treatment Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Brain Metastases Treatment Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Brain Metastases Treatment Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Brain Metastases Treatment Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Brain Metastases Treatment Drugs, Product Type & Application
2.7 Brain Metastases Treatment Drugs Market Competitive Situation and Trends
2.7.1 Brain Metastases Treatment Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Brain Metastases Treatment Drugs Players Market Share by Revenue
2.7.3 Global Brain Metastases Treatment Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Brain Metastases Treatment Drugs Retrospective Market Scenario by Region
3.1 Global Brain Metastases Treatment Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Brain Metastases Treatment Drugs Global Brain Metastases Treatment Drugs Sales by Region: 2018-2029
3.2.1 Global Brain Metastases Treatment Drugs Sales by Region: 2018-2023
3.2.2 Global Brain Metastases Treatment Drugs Sales by Region: 2024-2029
3.3 Global Brain Metastases Treatment Drugs Global Brain Metastases Treatment Drugs Revenue by Region: 2018-2029
3.3.1 Global Brain Metastases Treatment Drugs Revenue by Region: 2018-2023
3.3.2 Global Brain Metastases Treatment Drugs Revenue by Region: 2024-2029
3.4 North America Brain Metastases Treatment Drugs Market Facts & Figures by Country
3.4.1 North America Brain Metastases Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Brain Metastases Treatment Drugs Sales by Country (2018-2029)
3.4.3 North America Brain Metastases Treatment Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Brain Metastases Treatment Drugs Market Facts & Figures by Country
3.5.1 Europe Brain Metastases Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Brain Metastases Treatment Drugs Sales by Country (2018-2029)
3.5.3 Europe Brain Metastases Treatment Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Brain Metastases Treatment Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Brain Metastases Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Brain Metastases Treatment Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Brain Metastases Treatment Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Brain Metastases Treatment Drugs Market Facts & Figures by Country
3.7.1 Latin America Brain Metastases Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Brain Metastases Treatment Drugs Sales by Country (2018-2029)
3.7.3 Latin America Brain Metastases Treatment Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Brain Metastases Treatment Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Brain Metastases Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Brain Metastases Treatment Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Brain Metastases Treatment Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Brain Metastases Treatment Drugs Sales by Type (2018-2029)
4.1.1 Global Brain Metastases Treatment Drugs Sales by Type (2018-2023)
4.1.2 Global Brain Metastases Treatment Drugs Sales by Type (2024-2029)
4.1.3 Global Brain Metastases Treatment Drugs Sales Market Share by Type (2018-2029)
4.2 Global Brain Metastases Treatment Drugs Revenue by Type (2018-2029)
4.2.1 Global Brain Metastases Treatment Drugs Revenue by Type (2018-2023)
4.2.2 Global Brain Metastases Treatment Drugs Revenue by Type (2024-2029)
4.2.3 Global Brain Metastases Treatment Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Brain Metastases Treatment Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Brain Metastases Treatment Drugs Sales by Application (2018-2029)
5.1.1 Global Brain Metastases Treatment Drugs Sales by Application (2018-2023)
5.1.2 Global Brain Metastases Treatment Drugs Sales by Application (2024-2029)
5.1.3 Global Brain Metastases Treatment Drugs Sales Market Share by Application (2018-2029)
5.2 Global Brain Metastases Treatment Drugs Revenue by Application (2018-2029)
5.2.1 Global Brain Metastases Treatment Drugs Revenue by Application (2018-2023)
5.2.2 Global Brain Metastases Treatment Drugs Revenue by Application (2024-2029)
5.2.3 Global Brain Metastases Treatment Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Brain Metastases Treatment Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer AG Brain Metastases Treatment Drugs Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Pfizer Inc.
6.2.1 Pfizer Inc. Corporation Information
6.2.2 Pfizer Inc. Description and Business Overview
6.2.3 Pfizer Inc. Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Pfizer Inc. Brain Metastases Treatment Drugs Product Portfolio
6.2.5 Pfizer Inc. Recent Developments/Updates
6.3 Eli Lilly & Company
6.3.1 Eli Lilly & Company Corporation Information
6.3.2 Eli Lilly & Company Description and Business Overview
6.3.3 Eli Lilly & Company Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly & Company Brain Metastases Treatment Drugs Product Portfolio
6.3.5 Eli Lilly & Company Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis AG Brain Metastases Treatment Drugs Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sanofi Brain Metastases Treatment Drugs Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 F. Hoffmann-La Roche Ltd.
6.6.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.6.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.6.3 F. Hoffmann-La Roche Ltd. Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 F. Hoffmann-La Roche Ltd. Brain Metastases Treatment Drugs Product Portfolio
6.6.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.7 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 AstraZeneca Brain Metastases Treatment Drugs Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 GlaxoSmithKline
6.8.1 GlaxoSmithKline Corporation Information
6.8.2 GlaxoSmithKline Description and Business Overview
6.8.3 GlaxoSmithKline Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 GlaxoSmithKline Brain Metastases Treatment Drugs Product Portfolio
6.8.5 GlaxoSmithKline Recent Developments/Updates
6.9 Merck & Co., Inc.
6.9.1 Merck & Co., Inc. Corporation Information
6.9.2 Merck & Co., Inc. Description and Business Overview
6.9.3 Merck & Co., Inc. Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Merck & Co., Inc. Brain Metastases Treatment Drugs Product Portfolio
6.9.5 Merck & Co., Inc. Recent Developments/Updates
6.10 AngioChem Inc
6.10.1 AngioChem Inc Corporation Information
6.10.2 AngioChem Inc Description and Business Overview
6.10.3 AngioChem Inc Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 AngioChem Inc Brain Metastases Treatment Drugs Product Portfolio
6.10.5 AngioChem Inc Recent Developments/Updates
6.11 Mayo Clinic
6.11.1 Mayo Clinic Corporation Information
6.11.2 Mayo Clinic Brain Metastases Treatment Drugs Description and Business Overview
6.11.3 Mayo Clinic Brain Metastases Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mayo Clinic Brain Metastases Treatment Drugs Product Portfolio
6.11.5 Mayo Clinic Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Brain Metastases Treatment Drugs Industry Chain Analysis
7.2 Brain Metastases Treatment Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Brain Metastases Treatment Drugs Production Mode & Process
7.4 Brain Metastases Treatment Drugs Sales and Marketing
7.4.1 Brain Metastases Treatment Drugs Sales Channels
7.4.2 Brain Metastases Treatment Drugs Distributors
7.5 Brain Metastases Treatment Drugs Customers
8 Brain Metastases Treatment Drugs Market Dynamics
8.1 Brain Metastases Treatment Drugs Industry Trends
8.2 Brain Metastases Treatment Drugs Market Drivers
8.3 Brain Metastases Treatment Drugs Market Challenges
8.4 Brain Metastases Treatment Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
